News & Updates

Show Multimedia Only

Mitapivat cuts transfusion burden in TD thalassaemia

27 Dec 2024 by

In adults with transfusion-dependent (TD*) α- or β-thalassaemia, mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, significantly reduces transfusion burden, with durable responses up to 36 weeks, findings from the phase III ENERGIZE-T study have shown.

Mitapivat cuts transfusion burden in TD thalassaemia

27 Dec 2024

New UC guideline endorses early use of advanced therapies

27 Dec 2024 by

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

27 Dec 2024

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024 by

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024

Novel vaccine passes phase II trial in virally suppressed CHB

26 Dec 2024

Therapeutic vaccination with ChAdOx1-HBV/MVA-HBV (VTP-300) has generated CD4+ and CD8+ cells and reduced HBsAg in a subset of chronic hepatitis B (CHB) patients with baseline values <100 IU/ml, as shown in a phase Ib/IIa trial. Moreover, a significant decrease in surface antigen occurs when the vaccine is combined with low-dose nivolumab.

Novel vaccine passes phase II trial in virally suppressed CHB

26 Dec 2024

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

26 Dec 2024 by

In the final 2-year analysis of the EBMT-SAAWP* RACE** study, the addition of eltrombopag to standard immunosuppressive treatment (IST) comprising horse antithymocyte globulin (hATG) plus cyclosporin A (CsA) improves long-term outcomes as frontline therapy for severe aplastic anaemia/very severe aplastic anaemia (SAA/vSAA).

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

26 Dec 2024

PPI use raises risk of intestinal Behçet disease

24 Dec 2024

Treatment with proton pump inhibitors (PPIs) may contribute to a higher incidence of intestinal Behçet Disease (BD) in patients with BD, suggest the results of a study.

PPI use raises risk of intestinal Behçet disease

24 Dec 2024

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

The use of the antiandrogen enzalutamide in patients with granulosa cell ovarian tumour (GCT) falls short in terms of significant radiological response or clinical benefit, according to a phase II trial.

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

Newer hepatitis B vaccine provides superior protection for people with HIV

23 Dec 2024 by

People living with HIV who have no history of hepatitis B virus (HBV) infection or documented response to vaccination appear to have a stronger immune response to the hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) than that with an aluminum hydroxide adjuvant (HepB-alum).

Newer hepatitis B vaccine provides superior protection for people with HIV

23 Dec 2024

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

23 Dec 2024

The orally available and systemically acting small molecule modulator of sirtuin 6 (SIRT6) IMU-856 for coeliac disease demonstrates clinical activity with favourable safety profile, according to data from a phase 1 trial.

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

23 Dec 2024

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

22 Dec 2024

QX004N, a humanized IgG1λ monoclonal antibody targeting IL-23, is superior to placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I trial.

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

22 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Mitapivat cuts transfusion burden in TD thalassaemia

Mitapivat cuts transfusion burden in TD thalassaemia

New UC guideline endorses early use of advanced therapies

New UC guideline endorses early use of advanced therapies

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Novel vaccine passes phase II trial in virally suppressed CHB

Novel vaccine passes phase II trial in virally suppressed CHB

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

PPI use raises risk of intestinal Behçet disease

PPI use raises risk of intestinal Behçet disease

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Newer hepatitis B vaccine provides superior protection for people with HIV

Newer hepatitis B vaccine provides superior protection for people with HIV

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis